BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Norris Medicines Ltd. Share Price

NSE
BSE

BSE : 524414

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

High

Price Summary

Previous Close ₹15.22
Day's Range ₹14.00 - ₹15.22
Open ₹14.00
52 Week Range ₹12.00 - ₹19.63
Volume 1,058
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs) 0.16
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.00
Price/Earning (TTM) 0.00
TTM EPS (₹) -0.37
P/E Ratio 0.00
Book Value(₹) -0.94
PAT Margin (%) -21.26
Face Value (₹) 10.00
ROCE(%) -10.11

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 14.57 58.2
Expenses N/A N/A
PBT -3.11 -11.78
Operating profit 0.0 0.0
Net profit -3.1 -12.38

Shareholding Pattern

Promoters (% Holding)

34.01%

Mutual funds (% Holding)

0.01%

Non-Institution (% Holding)

65.92%

FI/Banks/Insurance (% Holding)

0.06%

Government (% Holding)

0.00%

FII

0.00%

About Norris Medicines Ltd.

Founded 1990

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,47,236.04 1,843.50 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 2,49,673.20 9,369.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,87,460.49 4,978.80 3,480.60 - 3,480.60
Apollo Hospitals Enterprise Ltd. 1,27,608.88 8,935.65 6,696.50 - 6,696.50
Lenskart Solutions Ltd. 1,20,568.70 691.30 0.00 - 0.00
Zydus Lifesciences Ltd. 1,11,520.93 1,124.90 835.50 - 835.50
Cipla Ltd. 1,11,484.47 1,354.35 1,165.70 - 1,165.70
Laurus Labs Ltd. 1,04,604.45 1,965.05 823.10 - 823.10
Max Healthcare Institute Ltd. 1,01,126.94 1,036.80 903.00 - 903.00
Manipal Health Enterprises Ltd. 96,430.30 718.10 625.45 - 625.45
no-content No Records Found

Latest News

Jul
3
2026
EQUITY Posted on Jul 3rd 2026

Norris Medicines informs about certificate

Norris Medicines has enclosed confirmation certificate received from Registrar and Transfer Agent, Purva Sharegistry (India) as per Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended 30 June, 2026. 
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
11
2026
EQUITY Posted on Sep 11th 2026

Sigachi Industries informs about newspapers publication

Sigachi Industries has informed that the Corrigendum to Notice of Extra-Ordinary General Meeting of the company to be held on Tuesday, September 15, 2026 has been published in the newspapers, Financial Express and Nava Telangana on September 10, 2026.The company has enclosed are the clippings from the aforesaid newspapers.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
11
2026
EQUITY Posted on Sep 11th 2026

Glenmark Pharmaceuticals informs about credit rating

Glenmark Pharmaceuticals has informed that it enclosed rating rationale issued by India Ratings and Research. 
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
11
2026
EQUITY Posted on Sep 11th 2026

Glenmark Pharmaceuticals informs about media release

Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A., a wholly-owned subsidiary of the company (Glenmark), today announced the launch of RYALTRIS® Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older. The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (ANVISA) earlier this year. The company has attached media release in this regard.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
10
2026
EQUITY Posted on Sep 10th 2026

Shilpa Medicare informs about initiation of NCLT order on FTF Pharma

Pursuant to Regulation 30 of Listing Regulations, Shilpa Medicare has informed that the Hon’ble National Company Law Tribunal, Ahmedabad Bench -Court II, vide its order pronounced on September 9, 2026 in CP (IB) No. 346 (AHM) 2025, has admitted the application filed under Section 9 of the Insolvency and Bankruptcy Code, 2016 (IBC) by Immacule Lifesciences against FTF Pharma, a Wholly Owned Subsidiary of Shilpa Medicare, and has ordered commencement of the Corporate Insolvency Resolution Process (“CIRP”) against FTF Pharma. The Company is in discussions with its legal advisors to evaluate the overall legal position and the future course of action for the same. We will provide requisite updates at appropriate time on any further development on the matter. A copy of the order of the Hon’ble NCLT dated September 9, 2026 is enclosed for information and records. The requisite details as prescribed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Norris Medicines Ltd. ?

The current share price of Norris Medicines Ltd. is ₹15.22 as of 2026-09-11.

The market capitalisation of Norris Medicines Ltd. is ₹14.50 as of 2026-09-10.

The 1-year return of Norris Medicines Ltd. is -1.62% as of 2025-09-10.

The P/E ratio of Norris Medicines Ltd. is 0.00 as of 2026-09-11.

The 52-week high and low of Norris Medicines Ltd. are ₹19.63 and ₹12.00, respectively, as of 2026-09-11.

The dividend yield of Norris Medicines Ltd. is 0.0% as of2026-09-10.

You can buy Norris Medicines Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Norris Medicines Ltd. is Vimal Dhirendra Shah.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore